Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

• Authors: VAN EIMEREN T.; ANTONINI A.; BERG D.; BOHNEN N.; CERAVOLO R.; DRZEZGA A.; HÖGLINGER G.; HIGUCHI M.; LEHERICY S.; LEWIS S.; MONCHI O.; NESTOR P.; ONDRUS M.; PAVESE N.; PERALTA M.C.; PICCINI P.; PINEDA-PARDO J.A.; REKTOROVÁ Irena; RODRÍGUEZ-OROZ M.
• Year of publication: 2019
• Type: Article in Periodical
• Magazine / Source: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
• MU Faculty or unit: Central European Institute of Technology
• Web: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.dadm.2019.01.011
• Doi: http://dx.doi.org/10.1016/j.dadm.2019.01.011
• Keywords: Biomarker; CDB; CBS; MRI;MSA
• Description: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.